post-1

AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)

AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)

post-1

AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering

AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering

post-1

Artificial Intelligence Is Optimizing Drug Development

Artificial Intelligence Is Optimizing Drug Development

post-1

AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock

AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock

post-1

AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million

AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million

post-1

AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock

AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock

post-1

AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment

AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment

post-1

Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.

Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.

post-1

AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board

AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board

post-1

Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics

Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics

post-1

AIkido Pharma Adds Inventor Dr. Neil H. Bander, M.D. to Scientific Advisory Board

New Board Member Brings Expertise in Oncology Research

post-1

Aikido Pharma Secures Early Interest in Next Generation Radiotherapy

Currently in Human Phase 2 Trials for Treatment of Prostate Cancer

post-1

AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements

AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements

post-1

AIkido Pharma Inc. Executes Licensing Agreement for Psilocybin for Cancer Applications

AIkido Pharma Inc. Executes Licensing Agreement for Psilocybin for Cancer Applications

post-1

AIkido Pharma Announces Publication of Artificial Intelligence-Machine Learning Sponsored Research Program for Pancreatic Cancer

AIkido Pharma Announces Publication of Artificial Intelligence-Machine Learning Sponsored Research Program for Pancreatic Cancer

post-1

AIkido Pharma Inc. Announces Results of 2020 Annual Stockholder Meeting

AIkido Pharma Inc. Announces Results of 2020 Annual Stockholder Meeting

post-1

AIkido Pharma Inc. Announces Publication of Favorable Peer Reviewed Study of Newly Licensed Antiviral Compounds

AIkido Pharma Inc. Announces Publication of Favorable Peer Reviewed Study of Newly Licensed Antiviral Compounds

post-1

AIkido Pharma Inc. Provides Update on Its Next-Generation Chemotherapeutic Treatment DHA-dFdC

AIkido Pharma Inc. Provides Update on Its Next-Generation Chemotherapeutic Treatment DHA-dFdC

post-1

AIkido Pharma Announces Update On Its Use Of Artificial Intelligence

AIkido Pharma Announces Update On Its Use Of Artificial Intelligence

post-1

AIkido Pharma Inc. Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)

AIkido Pharma Inc. Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)